The BVDzero Committee, consisting of industry experts from various countries, in collaboration with a representative of the World Association for Buiatrics, identified outstanding 12 veterinary students from around the world who can help address the ever-changing industry and the health, food, and welfare needs of the veterinary community.
The Congress represents a top industry event to network and learn where the students will have a unique opportunity to improve their veterinary knowledge about cattle medicine, meet top subject matter experts and key opinion leaders as well the Boehringer Ingelheim Animal Health Business Unit cattle team.
The 12 BVDzero Scholarship Programme winners are as follows:
· Allison Hale, US
· Amy Birch, Australia
· Bruna Mendes, Brazil
· Eugenia Ishaku, Nigeria
· Jessie Hesseling, The Netherlands
· Jia Cheng, China
· Lovina Ikwe, Nigeria
· Mariel Burquez, Mexico
· Samuel Kalis, US
· Savannah Basham, US
· Tahia Logna, Bangladesh
· William Philips, UK
“We were delighted to see such huge interest by students from around the world. We received 454 submissions in total. Through this initiative, we want to draw attention to and create awareness of BVD by veterinary students. On top of it, our objective is to make connections with those who may wish to build their career with Boehringer Ingelheim, joining us in our effort to create the future of animal health,” shared Serkan Erkovan, Senior Global Manager for Ruminant Business at Boehringer Ingelheim.
Congratulations to all the winners!
Boehringer Ingelheim is the second largest animal health business in the world, with net sales of almost $4.7 billion (3.9 billion euros) worldwide in 2018, about 10,000 employees and a presence in more than 150 markets. We have pioneered advancements in vaccines, parasite-control products and therapeutics that limit pain and slow disease, and we aim to create the future of animal wellbeing for pets, horses and livestock by focusing on prevention.
Boehringer Ingelheim’s Animal Health Business has a significant presence in the United States, with more than 3,000 employees in places that include Georgia, Missouri, Iowa, Minnesota, New Jersey and Puerto Rico. To learn more, visit www.boehringer-ingelheim.us, www.facebook.com/BoehringerAHUS or www.twitter.com/Boehringer_AH.
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas: human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around $20.7 billion (17.5 billion euros). R&D expenditure of about $3.8 billion (3.2 billion euros), corresponded to 18.1 per cent of net sales.
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.
©2019 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All Rights Reserved.